Trastuzumab, Paclitaxel, Cisplatin, and Radiation for Adenocarcinoma of the Esophagus: A Phase I Study #

Howard Safran, Thomas A. DiPetrillo, Ahmed Nadeem, Margaret M. Steinhoff, Umadevi Tantravahi, Ritesh Rathore, Harold J. Wanebo, M. A. HUGHES, C. Maia, James Tsai,

Cancer Investigation · 2004 · 57 citations · 0 references

Abstract

HER-2/neu is overexpressed in approximately one-third of esophageal adenocarcinomas. Trastuzumab can be added at full dose to cisplatin, paclitaxel, and radiation. Future studies of trastuzumab in esophageal adenocarcinoma are indicated.